TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05336812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04699890

Intervention type: OTHER
Intervention: Blood sampling, questionnaires and specific exams
Description: Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
Study: NCT06056310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Description: Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
Study: NCT04580238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox 200 UNT Injection
Description: Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Non Botox based Standard of Care Treatments for Headache/Migraine
Description: Control Group will receive normal standard of care Non-Botox based interventions.
Study: NCT06521710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Somatic-Autonomic Nerve Grafting
Description: A one-sided graft using a genitofemoral (GFN) nerve graft between one obturator nerve and the corpora cavernosa
Study: NCT05876481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Product name: Psilocybin Pharmaceutical form: capsule, hard Dose number and units: 25 mg per day (8-hour dosing session) x 2 Route of administration: oral
Study: NCT05528055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCR-6920 capsule
Description: SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCR-6920 capsule
Description: SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCR-6920 capsule
Description: SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCR-6920 capsule
Description: SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
Study: NCT04515004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucoselect phytosome
Description: A standardized grape seed procyanidin extract complexed with soy phospholipid.
Study: NCT05383209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IVT
Description: Sham IVT
Study: NCT04862065

Intervention type: DEVICE
Group type: OTHER
Intervention: Alinity s Anti-HCV II
Description: For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study: NCT05870514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium for injection
Description: Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol
Study: NCT06468098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + Investigator's Choice SOC
Description: In this group, patients will receive IBI363 and Investigator's Choice SOC
Study: NCT05768100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,3-Butanediol
Description: 1,3-Butanediol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isovolumic placebo
Study: NCT05596955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine injection
Description: Extended release once-a-month buprenorphine injection . Study arm undergoes 2 fMRI examinations and weekly monitoring visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Injection
Description: Extended release once-a-month naltrexone injection. Study arm undergoes 2 fMRI examinations and weekly monitoring visits
Study: NCT05299398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily
Study: NCT05313789

Intervention type: DEVICE
Intervention: Analgesia Nociception Index (ANI)
Description: Monitorization of Analgesia Nociception Index in Intensive Care Patients

Intervention type: DEVICE
Intervention: Analgesia Nociception Index (ANI)
Description: Monitorization of Analgesia Nociception Index in Intensive Care Patients

Intervention type: DEVICE
Intervention: Analgesia Nociception Index (ANI)
Description: Monitorization of Analgesia Nociception Index in Intensive Care Patients
Study: NCT05936489

Intervention type: DRUG
Group type: OTHER
Intervention: Aceclidine + Brimonidine
Description: LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Aceclidine
Description: LNZ100 (Aceclidine) non-preserved ophthalmic solution
Study: NCT04692623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 MG
Description: Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
Study: NCT06349694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous MPN stimulation (T-MPNS)
Description: Transcutaneous MPN stimulation (T-MPNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: Transcutaneous tibial nerve stimulation (TTNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BT (Control group)
Description: Conventional bladder training
Study: NCT05218369

Intervention type: DRUG
Intervention: IL6 Antagonist
Description: Patients will receive IL-6 antagonist therapy at the consultant's discretion.
Study: NCT06457724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levilactobacillus brevis CNCM I-5566
Description: Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
Study: NCT05260268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEST Intervention
Description: The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
Study: NCT05034913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital photography measurements
Description: The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations.
Study: NCT05794035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery with additional moderate hypofractionation RT (15 fractions)
Description: After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm B: Surgery followed by moderate hypofractionation RT (15 fractions): 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone, without radiation post surgery
Description: Arm A: Surgery alone followed by surveillance

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Surgery with extreme hypo fractionation treatment (HF)
Description: After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm C= Surgery followed by extreme hypofractionation RT (5 fractions, 2 fractions/week): 30Gy in 5 fractions of 6Gy over 5 weeks to the operative bed.
Study: NCT05280717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IV infusion
Study: NCT05691881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY105
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
Study: NCT06125704

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate intensity walking or stepping
Description: 30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate intensity walking or stepping
Description: 30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).
Study: NCT05948241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online psychological support group
Description: 1. st Session: Presentation of the participants and the objectives of the group, which are the management of depression and the promotion of self-care. Discussion on heart failure and its clinical management. Arrangements will be made with these patients about confidentiality between the participants, as it is a group intervention where each participant can expose their personal issues.~2. nd Session: Discussion on depression and its clinical management. From the 3rd to the 11th Session: They will aim to offer support for the emotional demands of the participants, related to the daily and future challenges inherent in the care provided with HF, seeking to promote self-care. As it is a homogeneous group, it is expected to enable enriching exchanges within the group about changes in habits or adaptations to HF, since psychological support groups have this function.~12th Session: Closing and evaluation of participants. Scheduling for reassessment of instruments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard multidisciplinary care
Description: The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
Study: NCT05961267

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
Study: NCT05395000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videos
Description: A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videos
Description: A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
Study: NCT06344338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS stimulation
Description: In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TDCS sham-stimulation
Description: TDCS sham-stimulation
Study: NCT06159062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 162
Description: The investigational product 162 is a novel monoclonal antibody targeting HBsAg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo do not consist any active ingredients.
Study: NCT04309110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: or geko™ X-T3
Description: The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
Study: NCT05661344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study: NCT05107544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH INTENSITY INTERVAL TRAINING
Description: Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
Study: NCT06555185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potentiation warm-up protocol
Description: The intervention protocol consisted of i) 1st set - six hurdle jumps, with a distance of 70 cm between each, followed by a 15-m sprint with COD; (ii) 2nd set - six lateral hurdle jumps (three to the left and three to the right) followed by a 10-m sprint with COD; (iii) 3rd set - six bouncy strides, followed by a 15-m sprint with COD; (iv) 4th set - six broad jumps followed by a 10-m sprint with COD. All COD circuits had different configurations, changing the sprint distance and the angle of the COD curve. All repetitions and sets were separated by 90-second recovery intervals, and each set was performed three times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm-up protocol
Description: The usual warm-up consisted of (i) The first phase included dynamic stretching and drills to increase body temperature. This phase lasted 5-min and included slow jogging, light skipping, and dynamic stretches for hip flexors, glutes, quads, hamstrings, abductors, gastrocnemius and lower limb joints. (ii) The second phase was composed of exercises that intended to mimic specific movements of the football match, both with and without ball possession. This phase lasted 15 minutes and included exercises with and without possession of the ball, such as acceleration, COD, jumping over hurdles, and playful games with ball possession. In this group, the players only rested in a slow jog when they moved from the first to the second phase.
Study: NCT06199934

Intervention type: BIOLOGICAL
Intervention: Vaccination
Description: BNT162b2 vaccination
Study: NCT06085534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001
Description: Capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001
Description: Capsules for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001
Description: Capsules for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral use
Study: NCT04418778

Intervention type: BEHAVIORAL
Intervention: BEAR
Description: Building Empowerment and Resilience Therapy group
Study: NCT05123534

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.